Sort
130,381 grants matching “hiv”
International Research in Thailand
$925,647Steven Holland · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder
$925,573Luis J. Montaner · Wistar Institute · R01 · FY2022 · DA
Papillomavirus Virion Proteins and Vaccines
$925,516Douglas R. Lowy · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Institutional Collaboration between LSTM and CDC and Prevention on Malaria(U01)
$925,450Feiko Olaf Ter Kuile · Tmliverpool School Of Tropical Medicine · U01 · FY2013 · CK
Early neonatal treatment and immune quiescence
$925,357Louise Kuhn · Columbia University Health Sciences · U01 · FY2016 · HD
Models of SBIRT for Opioid Dependent Patients in the Emergency Department
$925,186Gail D'onofrio · Yale University · R01 · FY2008 · DA
NHP MHC COMPLEX ALLELE DISCOVERY AND TYPING TECHNOLOGY DEVELOPMENT - HIV/AIDS
$925,074Daniel Geraghty · Fred Hutchinson Cancer Research Center · N01 · FY2017 · AI
An Innovative Approach to Identify Correctors of Metabolic Complications in HIV
$925,072Pietro P Sanna · Scripps Research Institute, The · R01 · FY2025 · DK
Molecular pathogenesis and therapy innovation for Merkel cell carcinoma
$925,055Isaac Brownell · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2022 · AR
Immunity to novel T/F SHIVs: variability in the co-evolution of virus and host immunity
$924,975Garnett H Kelsoe · Duke University · R01 · FY2020 · AI
Vaccines Designed From Analysis of Recent HIV Infections
$924,689Vaxgen, Inc. · R44 · FY2004 · AI
Design and optimization of DL-NLTs and molecular adjuvants to increase potency and promote NAb formation in vivo
$924,582David B. Weiner · Wistar Institute · U19 · FY2025 · AI
Novel Ondansetron Formulation for Combination Treatment of Psychostimulant Abuse
$924,518Tong H Lee · Duke University · RC2 · FY2009 · DA
Transformative research on somatic gene recombination in the normal and Alzheimer's disease-related dementia brain
$924,514Jerold Chun · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2023 · AG
Transformative research on somatic gene recombination in the normal and Alzheimer's disease-related dementia brain
$924,514Jerold Chun · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2022 · AG
Transformative research on somatic gene recombination in the normal and Alzheimer's disease-related dementia brain
$924,514Jerold Chun · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2020 · AG
Transformative research on somatic gene recombination in the normal and Alzheimer's disease-related dementia brain
$924,514Jerold Chun · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2021 · AG
Transformative research on somatic gene recombination in the normal and Alzheimer's disease-related dementia brain
$924,514Jerold Chun · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2024 · AG
Therapeutic Use of an Enhanced Form of CD4-Ig
$924,262Michael R. Farzan · Scripps Florida · R37 · FY2021 · AI
Global HIV/AIDS Vaccine Enterprise
$924,240Kevin Osborne · National Institute Of Allergy And Infectious Diseases · Y01 · FY2020 · AI
Humanized PRO 140 for CCR5-Targeted Therapy of HIV
$924,217Progenics Pharmaceuticals, Inc. · R44 · FY2003 · AI
HIV Persistence During Suppressive Antiretroviral Therapy
$924,183Frank Maldarelli · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
HIV-1 Genetic Variation in Infected Individuals
$924,183Frank Maldarelli · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
UNIVERSITY OF P.R PEDIATRIC AIDS CLINICAL TRIALS UNIT
$924,180University Of Puerto Rico Med Sciences · U01 · FY2005 · AI
Multi-component, Targeted HIV Prevention for sub-Saharan Africa: PreventionRx
$924,150Connie L Celum · University Of Washington · R01 · FY2009 · AI